» Articles » PMID: 20153009

Induction of Antibody-mediated Neutralization in SIVmac239 by a Naturally Acquired V3 Mutation

Overview
Journal Virology
Specialty Microbiology
Date 2010 Feb 16
PMID 20153009
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Achieving humoral immunity against human immunodeficiency virus (HIV) is a major obstacle in AIDS vaccine development. Despite eliciting robust humoral responses to HIV, exposed hosts rarely produce broadly neutralizing antibodies. The present study utilizes simian immunodeficiency virus (SIV) to identify viral epitopes that conferred antibody neutralization to clone SIV/17E-CL, an in vivo variant derived from neutralization resistant SIVmac239. Neutralization assays using rhesus macaque monoclonal antibodies were performed on viruses engineered to express single or multiple amino acid mutations. Results identified a single amino acid mutation, P334R, in the carboxy-terminal half of the V3 loop as a critical residue that induced neutralization while retaining normal glycoprotein expression on the surface of the virus. Furthermore, the R334 residue yielded neutralization sensitivity by antibodies recognizing diverse conformational and linear epitopes of gp120, suggesting that neutralization phenotype was a consequence of global structural changes of the envelope protein rather than a specific site epitope.

Citing Articles

Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

White T, Bartesaghi A, Borgnia M, de la Cruz M, Nandwani R, Hoxie J J Virol. 2011; 85(23):12114-23.

PMID: 21937655 PMC: 3209358. DOI: 10.1128/JVI.05297-11.

References
1.
Regier D, Desrosiers R . The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1990; 6(11):1221-31. DOI: 10.1089/aid.1990.6.1221. View

2.
Parren P, Marx P, Hessell A, Luckay A, Harouse J, Cheng-Mayer C . Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001; 75(17):8340-7. PMC: 115078. DOI: 10.1128/jvi.75.17.8340-8347.2001. View

3.
Maecker H, Maino V . T cell immunity to HIV: defining parameters of protection. Curr HIV Res. 2004; 1(2):249-59. DOI: 10.2174/1570162033485294. View

4.
Rosen O, Sharon M, Quadt-Akabayov S, Anglister J . Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc Natl Acad Sci U S A. 2006; 103(38):13950-5. PMC: 1599894. DOI: 10.1073/pnas.0606312103. View

5.
Mascola J, Lewis M, VanCott T, Stiegler G, Katinger H, Seaman M . Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol. 2003; 77(19):10348-56. PMC: 228504. DOI: 10.1128/jvi.77.19.10348-10356.2003. View